Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.
Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects.
A German study of a new drug therapy for chronic lymphocytic leukemia was praised because the majority of the patients enrolled were elderly and had other, coexisting health issues.
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88% achieved complete remission after being treated with genetically modified versions of their own immune cells.
A group of researchers discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, has also proved successful in treating hairy cell leukemia.
Linear dose-response relationship for acute lymphoblastic leukemia and acute myeloid leukemia has been observed.
Targeted treatments for acute promyelocytic leukemia cause a cascade of molecular events that lead to cellular senescence and recovery. This action model could be activated in other types of cancers.
Scientists have discovered a genetic signature that implicates a key mechanism in the immune system as a driving force for a type of childhood leukemia.
A new study helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.
High-dose cytarabine in induction treatment improves the outcomes of adult patients with acute myeloid leukemia (AML).
For patients with previously untreated chronic lymphocytic leukemia and coexisting conditions, combining an anti-CD20 antibody with chemotherapy is associated with improved outcomes, according to a study.
Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.
Growing cord blood stem cells in a laboratory before transplanting them into patients with leukemia, lymphoma, and other blood cancers significantly improves survival, according to a new study.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a new study from researchers.
A genetic link specific to risk for childhood leukemia has been identified for the first time, according to a new study.
New research suggests that blocking a protein normally credited with suppressing leukemia may be a promising therapeutic strategy for an aggressive form of the disease called acute myeloid leukemia.
Unique virus-derived particles have been developed that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects.
New research suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.
A biomarker accessible in blood tests has been identified and validated. It could be used to predict which patients who have received stem cell transplants are at the highest risk for the potentially fatal immune response of graft-versus-host disease.
Treatment combining arsenic trioxide with standard care for APL was just as effective as conventional therapy in low-to-intermediate risk disease.
Using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions for acute lymphocytic leukemia patients.
Among patients with CLL, African Americans more commonly present with advanced disease and tend to have shorter survival times than whites despite receiving the same care.
Oral ibrutinib demonstrated durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma in one study, and showed a high frequency of durable remissions in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma in another study.
The drug targets interactions with the tumor microenvironment and promotes remission in patients with relapsed chronic lymphocytic leukemia, according to a study in the New England Journal of Medicine.
Treating patients with pediatric leukemia with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without added heart toxicity, according to a new study.
MicroRNA-155 has been identified as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia whose chromosomes look normal under the microscope.
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
Gossypol plus navitoclax may be effective in destroying resistant chronic lymphocytic leukemia (CLL) cells in the lymph nodes and bone marrow.
Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|